Hundreds of Tylenol ADHD and Autism Lawsuits Revived by Federal Appeals Court

A federal appeals court has reinstated over 500 lawsuits claiming that the use of Tylenol during pregnancy may be linked to autism and attention deficit hyperactivity disorder (ADHD) in exposed children. This ruling overturns a previous decision by a lower court that had dismissed these claims, allowing families to pursue their allegations against the drug’s manufacturer, Kenvue.

Lawsuits Linking Tylenol to Autism, ADHD

The product liability lawsuits in question stem from allegations that acetaminophen, the active ingredient in Tylenol, poses risks to fetal development when taken by pregnant women. Families have claimed that their children developed autism or ADHD as a result of prenatal exposure to this widely used pain reliever. The legal actions began gaining traction in 2022, leading to a consolidation of claims into a multidistrict litigation (MDL) in the Southern District of New York.

Initial Dismissal of the Tylenol Lawsuits

In December 2024, U.S. District Judge Denise Cote dismissed the product liability lawsuits, ruling that the expert testimony presented by the plaintiffs was not reliable enough to establish a causal link between Tylenol use during pregnancy and the development of autism or ADHD. This dismissal effectively halted the litigation, leaving many families without recourse.

Appeals Court Ruling Reverses Lower Court’s Decision

Last week, the 2nd U.S. Circuit Court of Appeals in Manhattan issued a ruling that reversed Judge Cote’s decision. The court found that the lower court had improperly excluded testimony from three expert witnesses who were prepared to provide evidence supporting the plaintiffs’ claims. These expert witnesses included Andrea Baccarelli, ⁠the dean of Harvard University’s School of Public Health; Brandon Pearson, a toxicologist at Columbia University; and Eric Hollander, a psychiatry ⁠professor at the Albert Einstein College of Medicine. The appeals court emphasized that the admissibility of expert testimony is crucial in determining the validity of scientific claims in court.

Key Points from the Appeals Court’s Ruling

The appeals court did not make a determination on whether Tylenol actually causes autism or ADHD. Instead, it focused on the procedural aspects of the claim, specifically the exclusion of expert testimony.

Circuit Judge Guido Calabresi stated that the experts’ analyses represented acceptable interpretations of scientific evidence, even in the face of disagreement within the scientific community.

The ruling allows the plaintiffs to present their expert witnesses in court, potentially strengthening their claims against Kenvue and other defendants, including major retailers like CVS, Walgreens, and Walmart.

Implications for Kenvue and Retailers

Kenvue, the manufacturer of Tylenol, has consistently denied any link between acetaminophen use during pregnancy and developmental disorders like autism and ADHD. Following the appeals court ruling, the company reiterated its position, stating that credible scientific evidence does not support the claims made by the plaintiffs. Kenvue plans to challenge the reliability of the plaintiffs’ expert testimony as the litigation progresses.

In response to the appeals court ruling, Kenvue’s shares experienced a slight decline, reflecting investor concerns about the potential financial implications of the revived Tylenol lawsuits. The company has expressed its commitment to defending its product and intends to explore all legal options available to contest the claims.

Scientific Debate Surrounding Tylenol Use in Pregnancy

The controversy surrounding acetaminophen use during pregnancy has intensified in recent years, with various studies suggesting a possible association between prenatal exposure to Tylenol and an increased risk of autism and ADHD. However, the scientific community remains divided on this issue, with some studies supporting the link while others do not.

Regulatory Responses to Acetaminophen Safety Concerns

In light of the ongoing debate about the alleged link between Tylenol and autism or ADHD, the U.S. Food and Drug Administration (FDA) has taken steps to update labeling for acetaminophen, advising pregnant women to use the medication with caution. This regulatory action underscores the need for further research into the safety of acetaminophen use during pregnancy.

The Path Forward for Plaintiffs With Tylenol Claims

With the appeals court’s decision, the plaintiffs in the Tylenol litigation now have the opportunity to present their claims in court, including the expert testimony that was previously excluded. This development could pave the way for a series of bellwether trials, which would allow both sides to gauge how juries respond to the evidence presented.

While the appeals court ruling does not guarantee a favorable outcome for the plaintiffs, it does provide them with a renewed chance to argue their claims. The results of any upcoming trials could have significant implications for Kenvue and the broader pharmaceutical industry, particularly regarding the safety of using over-the-counter medications like Tylenol during pregnancy.

A New Chapter in the Tylenol Autism/ADHD Litigation

The revival of these lawsuits marks a pivotal moment in the ongoing controversy surrounding Tylenol and its alleged links to autism and ADHD. The outcome of this litigation will not only impact the families involved but may also influence public perception and regulatory policies regarding the use of acetaminophen during pregnancy. As the legal proceedings unfold, it remains crucial for expectant mothers to stay informed about the potential risks associated with any medication they may consider taking during pregnancy.